Get started
Author

Joana Moreira

Observed name: Moreira, Joana
ORCID: 0009-0000-8649-941X
Observed ORCID: 0009-0000-8649-941X
OpenAlex ID: A5113001501
Adjunctive eslicarbazepine acetate: A pooled analysis of three phase III trials
2017 · Victor Biton, Joanne B. Rogin, et al. · Epilepsy & Behavior · 49
PDF
Effect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson's Disease
2022 · Joaquim J. Ferreira, Werner Poewe, et al. · Movement Disorders · 44
PDF
Efficacy and safety of eslicarbazepine acetate as adjunctive therapy for refractory focal-onset seizures in children: A double-blind, randomized, placebo-controlled, parallel-group, multicenter, phase-III clinical trial
2020 · Fenella Kirkham, Stéphane Auvin, et al. · Epilepsy & Behavior · 28
PDF
Pooled efficacy and safety of eslicarbazepine acetate as add‐on treatment in patients with focal‐onset seizures: Data from four double‐blind placebo‐controlled pivotal phase III clinical studies
2017 · Christian Elger, Mathias Koepp, et al. · CNS Neuroscience & Therapeutics · 28
PDF
Antiepileptogenesis after stroke—trials and tribulations: Methodological challenges and recruitment results of a Phase II study with eslicarbazepine acetate
2023 · Matthias J. Koepp, Eugen Trinka, et al. · Epilepsia Open · 26
PDF
Eslicarbazepine acetate exposure in pregnant women with epilepsy
2018 · Raquel Costa, Luís M. Magalhães, et al. · Seizure · 18
PDF
Safety and Tolerability of Adjunctive Eslicarbazepine Acetate in Pediatric Patients (Aged 4-17 Years) With Focal Seizures
2019 · Mark Mintz, Jesus E. Pina-Garza, et al. · Journal of Child Neurology · 14
Effects of adjunctive eslicarbazepine acetate on serum lipids in patients with partial-onset seizures: Impact of concomitant statins and enzyme-inducing antiepileptic drugs
2018 · Scott Mintzer, Robert T. Wechsler, et al. · Epilepsy Research · 14
PDF
Long‐term efficacy and safety of eslicarbazepine acetate monotherapy for adults with newly diagnosed focal epilepsy: An open‐label extension study
2020 · Eugen Trinka, Rodrigo Rocamora, et al. · Epilepsia · 12
PDF
Opicapone as an Add-on to Levodopa in Patients with Parkinson’s Disease Without Motor Fluctuations: Rationale and Design of the Phase III, Double-Blind, Randomised, Placebo-Controlled EPSILON Trial
2022 · Joaquim J. Ferreira, Werner Poewe, et al. · Neurology and Therapy · 11
PDF
Safety and efficacy of eslicarbazepine acetate for seizure prevention in patients with stroke at high risk of developing post-stroke epilepsy: a proof-of-concept, phase 2a, randomised, double-blind, placebo-controlled antiepileptogenesis trial
2026 · Matthias J Koepp, Eugen Trinka, et al. · The Lancet Neurology · 10
Opicapone as adjunct to levodopa in treated Parkinson's disease without motor complications: A randomized clinical trial
2025 · Joaquim J. Ferreira, Olivier Rascol, et al. · European Journal of Neurology · 10
PDF
Long-term therapeutic effect of eslicarbazepine acetate in children: An open-label extension of a cognition study in children aged 6–16 years
2022 · Pierangelo Veggiotti, Sergiusz Józwiak, et al. · Epilepsy & Behavior · 10
PDF
Safety of Eslicarbazepine Acetate in Elderly Versus Non-Elderly Patients with Focal Seizures: From Pooled Data of Clinical Studies to 8 Years of Post-Marketing Experience
2021 · Luís M. Magalhães, Raquel Costa, et al. · Drug Safety · 10
PDF
Serum sodium levels and related treatment‐emergent adverse events during eslicarbazepine acetate use in adults with epilepsy
2019 · Robert T. Wechsler, Rodney A. Radtke, et al. · Epilepsia · 9
PDF
Severity and burden of partial-onset seizures in a phase III trial of eslicarbazepine acetate
2015 · Joyce A. Cramer, Fulton F. Velez, et al. · Epilepsy & Behavior · 9
Lipid profile with eslicarbazepine acetate and carbamazepine monotherapy in adult patients with newly diagnosed focal seizures: post hoc analysis of a phase III trial and open-label extension study
2023 · Eugen Trinka, Rodrigo Rocamora, et al. · Therapeutic Advances in Neurological Disorders · 8
Long-term safety and tolerability of adjunctive eslicarbazepine acetate in children with focal seizures
2020 · Raman Sankar, Fenella J. Kirkham, et al. · Epilepsy & Behavior · 8
PDF
Long-term follow up of opicapone as add-on to levodopa in Parkinson's patients without motor fluctuations
2026 · Joaquim J. Ferreira, Olivier Rascol, et al. · Journal of Parkinson s Disease · 2
Long‐term effects of adjunctive eslicarbazepine acetate in adult Asian patients with refractory focal seizures: Post hoc analysis of a phase III trial
2024 · Sang Kun Lee, Sang Ahm Lee, et al. · Clinical and Translational Science · 2
Efficacy, safety, and tolerability of adjunctive eslicarbazepine acetate in patients with focal to bilateral tonic-clonic seizures
2023 · Steve Chung, Samy Guirguis, et al. · Epilepsy Research · 2
Co-administration of Carbamazepine with Eslicarbazepine Acetate Decreases Eslicarbazepine Exposure: A Population Pharmacokinetic Analysis (P3.243)
2014 · Blanca Vazquez, Robert Wechsler, et al. · Neurology · 2
The epsilon (early Parkinson with L-dopa/DDCi and opicapone) study in early Parkinson's disease: Design and rationale of a phase III, double-blind, randomized, placebo-controlled study
2021 · Joaquim Ferreira, Werner Poewe, et al. · Journal of the Neurological Sciences · 1
Long-term efficacy and safety of eslicarbazepine acetate (ESL) monotherapy: results from BIA-2093-311/EXT study –the 2-year open-label extension of the ESL study (BIA-2093-311) (4165)
2020 · Eugen Trinka, Ana Pereira, et al. · Neurology · 1
Safety and Tolerability of Adjunctive Eslicarbazepine Acetate (ESL) in Pediatric Patients (Aged 4–17 Years) with Partial-Onset (Focal) Seizures (POS) (P5.269)
2018 · Mark Mintz, Jesus Pina-Garza, et al. · Neurology · 1
Works count: 41
Citation count: 329
H-index: 10
I10-index: 14
Year
Topic
Type